FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics by Douglas J. Pisano (Editor), David S. Mantus (Editor)

BUY IT NEW

  • $199.95 Online price
    $159.96 Member price
    (Save 19%)
    Limited Time Offer! Everyone receives the Member Price on books.
    See Details
  • skip to cart
  • Add To List uiAction=GetAllLists&page=List&pageType=list&ean=9781420073546&productCode=BK&maxCount=100&threshold=3

GET FREE SHIPPING ON ORDERS OF $25 OR MORE

DELIVERY & GIFT DETAILS:

Usually ships within 24 hours

Delivery Time and Shipping Rates

Eligible for gift wrap & gift message.

BUY IT USED

4 copies from $166.39

See All Available

Pick Me Up

Reserve it at BN.com & pick it up in 60 minutes at your local store.

Enter a zip code

(Hardcover - REV)

  • Pub. Date: August 2008
  • 464pp
  • Sales Rank: 202,293
    Buy it Used: 4 copies from $166.39 See All Available

    Customers who bought this also bought

     
    • Overview
    • Editorial Reviews
    • Features

    Product Details

    • Pub. Date: August 2008
    • Publisher: Taylor & Francis, Inc.
    • Format: Hardcover, 464pp
    • Sales Rank: 202,293

    Synopsis

    Examines harmonization of the US Federal Food, Drug, and Cosmetic Act with international regulations as they apply to human drug and device development, research, manufacturing, and marketing. The Second Edition focuses on the new drug approval process, cGMPs, GCPs, quality system compliance, and corresponding documentation requirements. Written in a jargon-free style, it draws information from a wide range of resources. It demystifies the inner workings of the FDA and facilitates an understanding of how it operates with respect to compliance and product approval.

    FDA Regulatory Affairs:


    • provides a blueprint to the FDA and drug, biologic, and medical device development
    • offers current, real-time information in a simple and concise format
    • contains a chapter highlighting the new drug application (NDA) process
    • discusses FDA inspection processes and enforcement options
    • includes contributions from experts at companies such as Millennium and Genzyme, leading CRO's such as PAREXEL and the Biologics Consulting Group, and the FDA

    Three all-new chapters cover:


    • clinical trial exemptions
    • advisory committees
    • provisions for fast track

    Customer Reviews

    • Reader Rating:
    Be the first to write a review!